Skip to main content
Top
Published in: Journal of Cancer Education 1/2019

01-02-2019

Implementation of a Novel Medical School Multidisciplinary and Interprofessional Oncology Curriculum: a Mixed Method Study

Authors: Ryan P. McKillip, Olwen M. Hahn, Bartlomiej Bartkowiak, Carol A. Rosenberg, Olufunmilayo I. Olopade, Vineet M. Arora, Daniel W. Golden

Published in: Journal of Cancer Education | Issue 1/2019

Login to get access

Abstract

As the population of patients with cancer and survivors grows, physician knowledge of oncology clinical care and research is increasingly important. Despite this patient population growth, medical students and non-oncology physicians report insufficient oncologic and survivorship care training. First-year students at a single US medical school completing a summer research experience were invited to participate in integrated Scholars in Oncology-Associated Research (SOAR) program. SOAR seeks to broaden students’ understanding of multidisciplinary and interprofessional oncology clinical care and research. SOAR consists of three components: structured didactics, multidisciplinary tumor board attendance, and interprofessional shadowing. A mixed-methods approach investigated whether student knowledge improved after SOAR. Thirty-three students enrolled in SOAR (20 in 2015, 13 in 2016) and completed pre-assessments. Twenty-five (75.8%) students completed SOAR and post-assessments. Self-reported understanding of clinical (2[2, 3] vs. 4[4], p < 0.01) and research oncology (2[2, 3] vs. 4[4], p < 0.01) improved after SOAR. Understanding of individual disciplines also significantly improved. When describing clinical oncology, responses written post-SOAR were more comprehensive, averaging 3.7 themes per response vs. 2.8 on pre-assessments (p = 0.03). There were more references to “survivorship” as a component of oncology on post-assessments (0[0.0%] vs. 7[28.0%], p < 0.01) and “screening/prevention” (2[6.1%] vs. 7[28.0%], p = 0.03). Additionally, students more often described cancer care as a continuum on post-assessments (4[12.1%] vs. 11[44.0%], p = 0.01). A structured didactic and experiential introduction to oncology, SOAR, was successfully piloted. SOAR improved participant understanding of oncology and its distinct clinical and research disciplines. Future work will focus on expanding SOAR into a longitudinal oncology curriculum.
Appendix
Available only for authorised users
Literature
5.
go back to reference Akthar AS, Hellekson CD, Ganai S et al (2016) Interdisciplinary oncology education: a national survey of trainees and program directors in the United States. J Cancer Educ. doi:10.1007/s13187-016-1139-6 Akthar AS, Hellekson CD, Ganai S et al (2016) Interdisciplinary oncology education: a national survey of trainees and program directors in the United States. J Cancer Educ. doi:10.​1007/​s13187-016-1139-6
6.
go back to reference Committee on Improving the Quality of Cancer Care Addressing the challenges of an aging population, board on health care services, institute of medicine (2013) delivering high-quality cancer care: charting a new course for a system in crisis. National Academies Press (US), Washington (DC) Committee on Improving the Quality of Cancer Care Addressing the challenges of an aging population, board on health care services, institute of medicine (2013) delivering high-quality cancer care: charting a new course for a system in crisis. National Academies Press (US), Washington (DC)
7.
Metadata
Title
Implementation of a Novel Medical School Multidisciplinary and Interprofessional Oncology Curriculum: a Mixed Method Study
Authors
Ryan P. McKillip
Olwen M. Hahn
Bartlomiej Bartkowiak
Carol A. Rosenberg
Olufunmilayo I. Olopade
Vineet M. Arora
Daniel W. Golden
Publication date
01-02-2019
Publisher
Springer US
Published in
Journal of Cancer Education / Issue 1/2019
Print ISSN: 0885-8195
Electronic ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-017-1264-x

Other articles of this Issue 1/2019

Journal of Cancer Education 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine